雷珠单抗与康柏西普治疗白内障术后黄斑水肿的临床效果观察

中国药物评价 ›› 2023, Vol. 40 ›› Issue (6): 525-529.

雷珠单抗与康柏西普治疗白内障术后黄斑水肿的临床效果观察

陈海波1，许超2，李娟2

1.焦作复明眼科医院，河南焦作 454950；
2.焦作市人民医院，河南焦作 454150

收稿日期:2023-09-14 修回日期:2023-09-28 出版日期:2023-12-28 发布日期:2023-12-28
基金资助:
河南省医学科技攻关计划联合共建项目 LHGJ20220928

Clinical Effect of Leizumab and Compaximab in the Treatment of Macular Edema after Cataract Operation#br#

1.Jiaozuo Fuming Eye Hospital， Henan Jiaozuo 454950， China；
2.Jiaozuo People′s Hospital， Henan Jiaozuo 454150， China

Received:2023-09-14 Revised:2023-09-28 Online:2023-12-28 Published:2023-12-28

摘要/Abstract

摘要： 目的：观察比较雷珠单抗与康柏西普治疗白内障术后黄斑水肿（Pseudophakic cystoid macular edema，PCEM）临床效果及安全性。方法：选取我院2021年5月至2023年3月收治的89例PCEM患者，根据治疗方案将其分为对照组、观察组。对照组44例采用康柏西普治疗，观察组45例采用雷珠单抗治疗。比较两组临床疗效、角膜神经纤维密度和长度、视力（BCVA）、眼压、黄斑厚度（CMT）、房水因子指标[白介素6（IL6）、IL37、血管内皮生长因子（VEGF）]及术后不良反应。结果：观察组治疗总有效率88.89%与对照组93.18%比较，无显著差异（P＞0.05）；注射1、2、3次后两组BCVA、眼压、CMT注射前比较均明显改善（P＜0.05），两组间比较，BCVA、眼压、CMT无显著差异（P＞0.05）；注药1、2、3次后两组CNFD与注药前比较无显著差异（P＞0.05），观察组CNFL与注药前比较无显著差异（P＞0.05），对照组CNFL与注药前、观察组明显降低（P＜0.05）；注药3次后，两组IL6、IL37、VEGF较治疗前均降低（P＜0.05），两组间比较，IL6、IL37、VEGF无显著差异（P＞0.05）；观察组不良反应发生率6.67%与对照组4.55%比较无显著差异（P＞0.05）。结论：雷珠单抗与康柏西普治疗PCEM的疗效相当，且安全性较好，但前者对角膜神经具有一定影响。

关键词: 白内障, 黄斑水肿, 雷珠单抗, 康柏西普, 角膜神经

Abstract: Objective： To observe and compare the clinical efficacy and safety of Leizumab and Comcaercep in the treatment of Pseudophakic cystoid macular edema (PCEM) after cataract surgery. Methods： Eightynine patients with PCEM admitted to our hospital from May 2021 to March 2023 were selected and divided into control group and observation group according to the treatment plan. The control group (44 cases) was treated with Compaplomp， and the observation group (45 cases) was treated with leizumab. The clinical efficacy， corneal nerve fiber density and length， visual acuity (BCVA)， intraocular pressure， macular thickness (CMT)， aqueous humor factors [interleukin6 (IL6)， IL37， vascular endothelial growth factor (VEGF)] and postoperative adverse reactions were compared between the two groups. Results： The total treatment efficiency of observation group was 88.89% compared with control group 93.18%， there was no significant difference (P>0.05). After 1， 2 and 3 injections， BCVA， IOP and CMT before injection were significantly improved (P<0.05)， but there were no significant differences in BCVA， IOP and CMT between the two groups (P>0.05). There was no significant difference in CNFD between the two groups after 1 infusion， 2 infusion and 3 infusion (P>0.05)， there was no significant difference in CNFL between the observation group and before infusion (P>0.05)， and CNFL was significantly decreased between the control group and before infusion and observation group (P<0.05). After 3 times of injection， IL6， IL37 and VEGF were decreased in 2 groups compared with before treatment (P<0.05)， and there were no significant differences in IL6， IL37 and VEGF between 2 groups (P>0.05). The incidence of adverse reactions in the observation group was 6.67% compared with 4.55% in the control group (P>0.05). Conclusion： The efficacy and safety of lezumab in the treatment of PCEM are comparable to that of Compaucept， but the former has a certain effect on corneal nerves.

Key words: Cataract, Macular edema, Leizumab, Compacept, Corneal nerve

中图分类号:

陈海波, 许超, 李娟. 雷珠单抗与康柏西普治疗白内障术后黄斑水肿的临床效果观察[J]. 中国药物评价, 2023, 40(6): 525-529.

CHEN Hai-bo, XU Chao, LI Juan. Clinical Effect of Leizumab and Compaximab in the Treatment of Macular Edema after Cataract Operation#br#[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(6): 525-529.

参考文献

[1] 隋文婕，唐于荣，万丽.视网膜病变对糖尿病性白内障患者行白内障超声乳化术后黄斑水肿发生的影响及相关因素分析[J]. 中国医师杂志，2022，24(1)：5963.
[2] 刘宏卓，王培玉，方梦园，等.糖尿病黄斑水肿患者白内障围手术期应用抗VEGF药物的疗效观察[J]. 眼科新进展，2022，42(2)：128131.
[3] 夏侯梨.雷珠单抗玻璃体内注射联合超声乳化治疗白内障合并糖尿病性黄斑水肿的疗效[J]. 检验医学与临床，2023，20(5)：677679.
[4] 郑华宾，宫月荣，曹晓宁，等.康柏西普治疗糖尿病患者白内障术后不同类型黄斑水肿的疗效[J]. 国际眼科杂志，2020，20(11)：19671970.
[5] 李凤鸣，谢立信.中华眼科学[J]. 北京：人民卫生出版社，2014：254255.
[6] 陈俊，刘彬彬，黄冰林，等.加味桃红五苓散联合普拉洛芬治疗白内障术后黄斑水肿的临床疗效观察[J]. 江西中医药大学学报，2021，33(4)：3134.
[7] 朱晶，吴超琼，鲁铭，等.自拟益气利水方联合康柏西普治疗糖尿病患者白内障术后黄斑水肿的临床观察[J]. 南京中医药大学学报，2018，34(3)：253256.
[8] 皇甫镜如.白内障术后黄斑水肿的诊治新进展[J]. 中华实验眼科杂志，2019，37(4)：312315.
[9] 任师杰，罗翠平，雷建平.玻璃体内注射曲安奈德与康柏西普治疗白内障术后黄斑水肿的效果比较[J]. 中国实用医刊，2021，48(23)：101104.
[10] 江立.房水ES、VEGF和PDGF水平与2型糖尿病合并白内障术后黄斑水肿的临床研究[J]. 检验医学与临床，2022，19(13)：17991803.
[11] 简飞龙，廖锐，段娜.雷珠单抗联合激光手术治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察[J]. 海南医学，2022，33(17)：22262229.
[12] 程岩，刘国英.雷珠单抗与康柏西普玻璃体腔注射治疗糖尿病性黄斑水肿的临床疗效及安全性对比[J]. 反射疗法与康复医学，2021，2(22)：7780.
[13] 王韬.雷珠单抗和康柏西普玻璃体腔注射治疗视网膜分支静脉阻塞引起的黄斑水肿患者的有效性[J]. 中国药物经济学，2022，17(2)：3235.
[14] Bekmez S， Cakmak H， Kocaturk T， et al. Biomechanical properties of the cornea following intravitreal ranibizumab injection[J]. Graefes Arch Clin Exp Ophthalmol，2021，259(3)：691696.
[15] 祁媛媛，崔林，张莉，等.反复玻璃体腔注射雷珠单抗与阿柏西普对黄斑水肿患者角膜神经的影响[J]. 国际眼科杂志，2023，23(5)：848851.